NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Take-Two Interactive reported fiscal fourth-quarter revenue that topped analysts’ expectations, but the gaming company's net loss and forecast disappointed.
Applied Materials beat analyst expectations for earnings but missed on revenue. The company said that customer demand hasn’t changed due to an uncertain economic environment. Applied Materials’ outlook for the third quarter included wide ranges for revenue and adjusted earnings per share.
Fast-casual restaurant company Cava reported revenue and earnings that handily beat expectations. Same-restaurant sales growth of 10.8% was especially impressive. The company's forecast calls for same-restaurant sales growth to decelerate as the year goes on.
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BOLT
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: TECH
/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the...